HENDERSON, Nev., April 24, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTC: UEEC), (“UHP” or “the company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it had retained IQVIA Inc. to conduct a U.S. market commercialization study for HemoStyp. The primary purpose of the study will be to assist the company and Société Générale in its previously announced Review of Strategic Alternatives (https://www.unitedhealthproductsinc.com/press-releases/2018/11/28/united-health-products-united-health-engages-socit-gnrale-to-undertake-strategic-review). In addition, IQVIA will perform qualitative primary market research, and do medical device supply audits using its proprietary databases. IQVIA’s work is expected to be completed in the near future.
IQVIA, a publicly traded company whose stock is listed on the NYSE (IQV), is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 58,000 employees, IQVIA conducts operations in more than 100 countries. https://www.iqvia.com/
About United Health Products
United Health Products develops, manufactures, and markets patented hemostatic gauze for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all-natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
United Health Products, Inc.
PAN Consultants Ltd.